DiaSorin S.p.A.
DiaSorin S.p.A.
- Market cap
- $4.49B
- P/E ratio
- 24.25
Your view on DSRLF
Overview
What the company does, where it operates, and who runs it.
About DiaSorin S.p.A.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Carlo Rosa
- Headquarters
- Via Crescentino snc, Saluggia, VC, IT
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Carlo Rosa
- Headquarters
- Via Crescentino snc, Saluggia, VC, IT
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China.
The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample.
It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for DiaSorin S.p.A. from FRC's valuation model, read against the market price. DSRLF last traded at $83.28, 24.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for DiaSorin S.p.A.. Starting points for DiaSorin S.p.A.: P/E 24.2, EPS $3.78, beta 0.62 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for DiaSorin S.p.A.. DiaSorin S.p.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for DiaSorin S.p.A.. Trailing twelve-month EPS for DiaSorin S.p.A. stands at $3.78. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Hold
Analyst ratings
4 ratings- Strong Buy0
- Buy1
- Hold2
- Sell1
- Strong Sell0
Earnings per share estimates
| Per share | This quarterSep 2026 | Next quarterDec 2026 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | EUR 2.21 | EUR 2.22 | EUR 4.31 | EUR 4.81 |
| Lowest estimate | EUR 2.17 | EUR 2.18 | EUR 4.24 | EUR 4.65 |
| Highest estimate | EUR 2.24 | EUR 2.25 | EUR 4.39 | EUR 4.96 |
| Number of analysts | 1 | 1 | 2 | 2 |
| A year ago | EUR 0.09 | EUR 1.06 | EUR 2.77 | — |
| Growth vs a year ago | +2336.5% | +109.1% | +55.6% | — |
Revenue estimates
| Total | This quarterSep 2026 | Next quarterDec 2026 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | EUR 562.59M | EUR 565.40M | EUR 1.22B | EUR 1.30B |
| Lowest estimate | EUR 555.21M | EUR 557.99M | EUR 1.19B | EUR 1.27B |
| Highest estimate | EUR 568.66M | EUR 571.50M | EUR 1.25B | EUR 1.34B |
| Number of analysts | 4 | 3 | 8 | 8 |
| A year ago | EUR 280.00M | EUR 575.51M | EUR 1.19B | — |
| Growth vs a year ago | +100.9% | −1.8% | +2.1% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for DiaSorin S.p.A.. DiaSorin S.p.A. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| EDTXFSpectral Medical Inc. | Healthcare | OTC | $287.7M | ||
| ERFSFEurofins Scientific SE | Healthcare | OTC | $14.4B | ||
| FLGTFulgent Genetics, Inc. | Healthcare | NASDAQ | $673.9M | ||
| FUNIHypha Labs, Inc. | Healthcare | OTC | $4.0M | ||
| GHGuardant Health, Inc. | Healthcare | NASDAQ | $19.7B | ||
| GRALGRAIL, Inc. | Healthcare | NASDAQ | $4.5B | ||
| GSS.AXGenetic Signatures Limited | Healthcare | ASX | — | ||
| HLS.AXHealius Limited | Healthcare | ASX | — | ||
| HTGMQHTG Molecular Diagnostics, Inc. | Healthcare | OTC | $221 | ||
| IBX.AXImagion Biosystems Limited | Healthcare | ASX | — | ||
| IBXXFImagion Biosystems Limited | Healthcare | OTC | $2.2M | ||
| ICBUiMD Companies, Inc. | Healthcare | OTC | $7.7M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for DiaSorin S.p.A.. Coverage tracks DiaSorin S.p.A. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of DiaSorin S.p.A.